Weight Loss Injections in Glasgow: Making the Right Decision

Which injection is which, and why it matters before you decide

Mounjaro and Wegovy are both weekly subcutaneous injections, but they work differently. Mounjaro activates two gut-hormone pathways (GIP and GLP-1) making it the only dual-receptor agonist licensed for weight management in the UK. Wegovy activates the GLP-1 pathway alone. In practice, both slow gastric emptying, reduce appetite and help regulate blood sugar, but the clinical trial evidence suggests tirzepatide produces a larger average weight reduction. The SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine found tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes.

There is a misconception worth clearing up: these injections are not simply appetite suppressants you can take short-term and stop. They work alongside a reduced-calorie diet and increased activity, and the evidence base covers extended treatment periods, 68 to 72 weeks in the headline trials. A prescriber who tells you otherwise is worth questioning.

Which injection suits you is a clinical question. Your medical history, other medicines you take, and how you respond to a starting dose all shape the answer. That is what the consultation is for. If you want to explore a specific option before speaking to a prescriber, you can read more about how a weight loss injection works and what to expect from treatment. You can also read a fuller comparison of the two medicines on our overview of licensed weight loss injections, or find out whether the GL weight loss injection is the right fit for your circumstances.

NHS access in Glasgow versus going private

NHS access to these medicines is phased and criteria-based. Tirzepatide (Mounjaro) became available through some GP practices in England from April 2026, with the current cohort requiring a BMI of 40 or above plus four or more qualifying conditions, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. A second cohort covering BMI 35–39.9 with four or more of those conditions activated in June 2026. NHS England's guidance on weight management injections sets out the full criteria and the wraparound lifestyle support every NHS patient must engage with. Scotland, Wales and Northern Ireland have separate thresholds and different access routes; criteria differ, and availability varies by health board.

For most people in Glasgow right now, the NHS route either does not apply or involves a significant wait. Private treatment through a regulated online pharmacy does not require a referral or a waiting list. It does still require a genuine clinical assessment, a GPhC-registered prescriber reviews your consultation personally, not software, and that review happens the same day. If treatment is clinically appropriate, dispatch follows the same day for next-working-day delivery. That process works the same whether you live in Glasgow's West End or anywhere else in the UK.

For context on what private treatment typically costs, the cost of weight loss injections in the UK is explained in detail separately, prices have shifted substantially since Eli Lilly raised its list price in September 2025.

Eligibility: who qualifies for a private prescription

The licensed eligibility for both medicines is set out in their Summary Care Records and confirmed by NICE's appraisal of tirzepatide (TA1026): adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as prediabetes, hypertension, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance.

BMI alone never guarantees approval. The prescriber also considers your full medical picture: any contraindications, medicines you already take, and whether treatment is genuinely appropriate for you right now. People who are pregnant, breastfeeding, or actively trying to conceive are not suitable candidates, and neither are those under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma) require detailed prescriber discussion before any decision is made.

Transfer patients already on treatment elsewhere are welcome; our clinical team asks for evidence of your current dose and treatment history, which is standard clinical practice rather than extra bureaucracy.

Injection technique, storage and practical use

Both injections are given once weekly into the abdomen, thigh or upper arm, rotating the site each time. The pre-filled pens are designed to be used without clinical training, though reading the Patient Information Leaflet that comes with your treatment is not optional, it covers what to do if you miss a dose, how to handle the pen, and the exact storage instructions. Storage means refrigerated at 2–8°C; the allowable room-temperature window differs between products and pen sizes, so the leaflet is the authority, not general guidance you read online.

One practical note for anyone new to injecting: the needle is very fine and the mechanism on both pens minimises the sensation considerably. Most people who feel apprehensive before their first injection find it far less uncomfortable than they expected. If you are still deciding between options, our guide covering the three main weight loss injections available in the UK sets out how they compare on dose, mechanism and tolerability. Clean the injection site with an alcohol swab beforehand; if you need a supply, alcohol swabs are available alongside your treatment. Dispose of used pens in a proper sharps container, not household waste.

If you have questions about the process or want to understand what the consultation involves before you start, our frequently asked questions cover the most common ones. When you're ready, check your eligibility with a free consultation.